The Quiet Selloff Reshaping American Skin Care
Private equity groups have spent the last several years methodically acquiring independent dermatology practices across the country, and the pace is accelerating. What started as a niche investment thesis has turned into a full-scale consolidation wave touching every region – from suburban Ohio to the Texas Hill Country to the Pacific Northwest.
Why Dermatology Became a Target
Dermatology has a set of financial characteristics that make it attractive to institutional investors in ways that most medical specialties simply do not. The work is largely cash-pay or well-reimbursed by insurance, procedures are quick and high-volume, and the overhead model scales cleanly when you centralize administrative functions across multiple locations. A solo practitioner seeing 30 patients a day generates a reliable, recurring revenue stream – multiply that across 40 or 50 practices under one holding company, and the math becomes very interesting for investors with a five-to-seven year exit horizon.
The specialty also benefits from genuine demand that shows no sign of shrinking. Skin cancer screenings, acne treatment, cosmetic procedures, and chronic conditions like psoriasis and eczema create both medical and elective revenue lines within the same practice. That combination – medically necessary visits plus discretionary cosmetic spending – gives PE-backed dermatology platforms more financial stability than practices that rely on a single payer type or procedure category. When cosmetic volume slows, medical volume holds, and vice versa.
Physician owners are also, bluntly, exhausted. The administrative burden of running an independent practice has grown dramatically over the past decade. Prior authorizations, credentialing, electronic health records compliance, billing disputes, and staffing costs have made solo ownership feel less like professional independence and more like running a small business that never stops demanding attention. When a private equity group arrives with an offer that promises to remove those headaches – and includes a substantial check – a growing number of dermatologists are saying yes.
The typical deal structure involves the physician selling the practice to a platform company, receiving a combination of cash and equity in the platform, and then continuing to work as an employed physician under a multi-year contract. The equity component is designed to keep doctors engaged: if the platform grows and eventually sells to a larger buyer or goes public, the retained equity could pay out significantly. That pitch has proven persuasive, particularly for practitioners in their late 40s and 50s who want liquidity but are not yet ready to retire.
How the Platform Model Actually Works
Private equity investment in healthcare typically works through what the industry calls a “platform and bolt-on” strategy. A firm acquires one larger practice or a small group – the platform – and then systematically acquires smaller regional practices, attaching them to the existing infrastructure. This is the same playbook being used in regional veterinary medicine, where corporate consolidators have spent years rolling up independent clinics into national networks. The dermatology version follows nearly identical logic.
Once a practice is absorbed into the platform, the holding company typically centralizes the business functions that drain physician time: billing, HR, marketing, supply chain, and IT. The clinical operations nominally remain with the physicians, though that line has a way of blurring over time. Staffing decisions, scheduling protocols, and productivity expectations increasingly come from the management layer above the practice, not from the physician-owners who originally built it. That tension between corporate efficiency and clinical autonomy is the defining friction inside PE-backed dermatology groups.
Patient experience is where critics focus most of their concern. When a practice joins a platform, appointment availability sometimes improves in the short term – the new corporate owner may invest in hiring additional providers to increase throughput. But productivity metrics tied to revenue targets can push appointment times shorter, increase the use of physician assistants and nurse practitioners for visits that patients expected to have with a physician, and shift the practice’s marketing emphasis toward higher-margin cosmetic procedures. None of these changes are necessarily harmful, but they represent a reorientation of the practice’s priorities that patients and referring physicians do not always notice until it has already happened.
The competitive pressure on independent holdouts is real and growing. When a PE-backed group enters a market, it often has the capital to attract physicians with signing bonuses, offer higher base salaries than a solo practice can match, and invest in equipment and facility upgrades that independent practitioners cannot easily afford. Some independent dermatologists have responded by forming their own independent practice associations or joining hospital systems as a defensive move. Others have simply sold. The practices that have held out longest tend to be those with unusually strong patient loyalty, a niche subspecialty focus, or owners who have made clear they will not sell regardless of the offer.
The debt used to finance these acquisitions sits at the center of the long-term risk. PE firms typically use leveraged buyouts, meaning the acquired practices carry substantial debt as part of the transaction. That debt has to be serviced from the operating revenue of the practices themselves. If patient volume drops, if reimbursement rates get cut by major insurers, or if the interest rate environment makes refinancing expensive, the financial pressure flows directly into the clinical operations. Cost cuts, staff reductions, and tightened physician compensation are the most common responses when a platform runs into financial trouble – and some platforms already are.
What Comes After the Selloff
The exit strategies that PE firms are counting on depend heavily on continued appetite from larger buyers – either strategic acquirers in the healthcare sector or the public markets through an IPO. Both of those outcomes are harder to achieve when the underlying platforms are carrying heavy debt loads and operating in a regulatory environment that has become more attentive to corporate ownership of medical practices. Several states have strengthened enforcement of their corporate practice of medicine laws, which limit how much control non-physician entities can exercise over clinical decisions. Whether those laws meaningfully constrain PE-backed platforms or simply shape the legal architecture around them is a question that is still being tested in courts and regulatory agencies.
For patients in smaller cities and rural areas, the practical question is not about investment structure – it is about whether they will still be able to see a dermatologist at all. Many rural and mid-sized markets were already underserved before consolidation accelerated. If PE-backed platforms prioritize acquisitions in wealthier suburban markets with higher cosmetic revenue potential, the access gaps in less affluent areas will widen rather than narrow. The practices most likely to stay independent – or most likely to close when their aging physician-owners retire without a buyer – are often the ones serving communities that already have the fewest options.
